Apellis Pharmaceuticals Inc. (NASDAQ:APLS) finished Friday with an addition of $0.69 to close at $40.77, an upside of 1.72 percent. An average of 4,700,780 shares of common stock have been traded in the last five days. There was a gain of $10.12 in the past week, and it reached a new high 21 times over the past 12 months. The last 20 days have seen an average of 6,612,325 shares traded, while the 50-day average volume stands at 5,520,492.
APLS stock has increased by 26.97% in the last month. The company shares reached their 1-month lowest point of $19.83 on 08/07/23. With the stock rallying to its 52-week high on 06/14/23, shares of the company touched a low of $19.83 and a high of $94.75 in 52 weeks. It has reached a new high 22 times so far this year and lost -21.16% or -$10.94 in price. In spite of this, the price is down -56.97% from the 52-week high.
Insider Transactions
APLS stock investors should be aware that Apellis Pharmaceuticals Inc. (APLS) stock had its last reported insider trading activity 18 days ago on Aug 08. In this transaction, the insider spent $283,920. Director, Machiels Alec, disposed of 1,250 shares at a price of $64.79 on Jul 17. The insider now owns more than $80,988 worth of shares. Prior to that, Chief Scientific Officer Deschatelets Pascal went on to Sale 12,000 shares at $84.55 each on Jul 10. An amount of $1,014,600 was transacted.
Valuation Metrics
Apellis Pharmaceuticals Inc. (APLS) stock’s beta is 0.99. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 26.23, the price-to-book (PB) ratio at 14.11.
Financial Health
The quick ratio of Apellis Pharmaceuticals Inc. for the three months ended June 29 was 4.50, and the current ratio was 5.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.11 and a total debt to equity ratio of 1.24 for the quarter ending June 29. Apellis Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -786.41%. Its gross profit as reported stood at $69.79 million compared to revenue of $75.42 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Apellis Pharmaceuticals Inc.’s return on assets was -74.50%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$122.04 million in the quarter, while revenues of -$177.78 million were shrunk -27.81%. The analyst consensus anticipated Apellis Pharmaceuticals Inc.’s latest quarter earnings to come in at -$1.32 per share, but it turned out to be -$1.02, a 22.70% surprise. For the quarter, EBITDA amounted to -$106.88 million. Shareholders own equity worth $117.74 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Apellis Pharmaceuticals Inc. (APLS) price momentum. RSI 9-day as of the close on 25 August was 69.55%, suggesting the stock is Neutral, with historical volatility in this time frame at 139.81%.
As of today, APLS’s price is $36.62 +33.02% or $10.12 from its 5-day moving average. APLS is currently trading +27.33% higher than its 20-day SMA and -46.83% lower than its 100-day SMA. However, the stock’s current price level is -55.74% below the SMA50 and -14.38% below the SMA200.
The stochastic %K and %D were 87.41% and 83.11%, respectively, and the average true range (ATR) was 3.43. With the 14-day stochastic at 88.43% and the average true range at 3.57, the RSI (14) stands at 54.66%. The stock has reached 6.01 on the 9-day MACD Oscillator while the 14-day reading was at 8.14.
Analyst Ratings
JP Morgan downgraded Apellis Pharmaceuticals Inc. (NASDAQ: APLS) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for Apellis Pharmaceuticals Inc. (APLS) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell APLS, while 5 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 9 others rate it as a “buy”.
What is APLS’s price target for the next 12 months?
Analysts predict a range of price targets between $29.00 and $95.00, with a median target of $62.00. Taking a look at these predictions, the average price target given by analysts for Apellis Pharmaceuticals Inc. (APLS) stock is $64.29.
